Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tim Cook bestätigte in Berlin: Apple Watch kommt im April nach Deutschland
http://meedia.de/2015/03/03/tim-cook-bestaetigte-in-berlin-apple-watch-kommt-im-april-nach-deutschland/
Bonial Gruppe stellt App für Apple Watch vor
http://www.internetworld.de/mobile/app/bonial-gruppe-stellt-app-apple-watch-899854.html
Apple Stores sollen Spezial-Safe für Apple Watch Edition erhalten
http://www.it-times.de/news/apple-stores-sollen-spezial-safe-fur-apple-watch-edition-erhalten-109647/
Während die Preise für das Basismodell der Apple Watch bereits ab 349 US-Dollar beginnen, soll die Gold-Edition Apple Watch Edition bis zu 1.000 US-Dollar und mehr kosten, spekulieren Analysten. Das mit 18-karat Gold verzierte Modell ist entsprechend wertvoll. Hierfür will Apple offenbar seine Apple Stores mit einem Spezial-Safe ausstatten, in der die goldene Apple Watch Edition aufbewahrt werden soll, wie 9to5Mac berichtet. Der Spezial-Safe soll zudem mit einem MagSafe-Ladegerät ausgestattet, so dass die Uhr zu Demo-Zwecken jederzeit geladen werden kann. Apple soll bereits begonnen haben, erste Safes in seinen Apple Stores zu installieren. Offiziell bestätigen wollte dies der Mac-Hersteller noch nicht. (ami)
Apple’s iPhone Overtakes Android In US Sales For The First Time Since 2012
http://techcrunch.com/2015/02/04/apples-iphone-overtakes-android-in-us-sales-for-the-first-time-since-2012/?ncid=rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29
Apple Pay findet weitere Unterstützer bei Banken
http://www.it-times.de/news/apple-pay-findet-weitere-unterstutzer-bei-banken-109662/?src=rss
Nach einem Bericht von CNBC wollen künftig unter anderem auch die Alliant Credit Union, die First Niagara Bank und die Golden 1 Credit Union Apple Pay unterstützen. Zuletzt äußerte sich Apple CEO Tim Cook zuversichtlich über Apple Pay, wonach der mobile Zahlungsdienst an 750 Banken und Kreditgenossenschaften ausgerollt werden soll, so der Branchendienst 9to5Mac. Apple Pay ist ein Feature des mobilen Betriebssystems iOS 8.1, wodurch iPhone 6 bzw. iPhone 6 Plus Nutzer mit ihrem Smartphone bezahlen können. Auch mit der Apple Watch sollen künftig Nutzer via Apple Pay bezahlen können.
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
http://ih.advfn.com/p.php?pid=nmona&article=61691131
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D.
Hugh Cole, senior vice president and chief business officer at ARIAD Pharmaceuticals (Photo: Busines ...
Hugh Cole, senior vice president and chief business officer at ARIAD Pharmaceuticals (Photo: Business Wire)
Mr. Cole is a seasoned pharmaceutical executive with more than 25 years of industry experience and a deep background in rare and orphan pharmaceutical markets. Prior to joining ARIAD, he spent seven years at Shire Pharmaceuticals, most recently as senior vice president, strategic planning and program management and as a global franchise head, and before that, as vice president, business development. Previously, he held senior positions in business and corporate development at Oscient Pharmaceuticals (formerly Genome Therapeutics) and at Millennium Pharmaceuticals and its affiliates. Mr. Cole led numerous successful acquisitions both at Shire and Oscient.
“Hugh is a thoughtful and experienced executive who brings great value to our leadership team,” stated Dr. Berger. “He will be integral in seeking business and corporate development opportunities for ARIAD, including a commercial partnership for Iclusig® in Japan, as well as helping to further maximize our oncology pipeline.”
Hugh started his career as an investment analyst at Fred Alger Management and then as a Principal at the Wilkerson Group, a consulting and advisory firm. He has an AB degree in chemistry from Harvard and an MBA degree from the Wharton School at the University of Pennsylvania, focused on healthcare management and finance.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is trading in a range between 8.5 and 7.3 for several weeks. A break above the 8.56 level would give the stock momentum for a run to test the 9.20 level. Take a look at the technical daily chart above because the stock has some noticeable indicators suggesting that is ready to make a move. I notice that the MACD had a bullish crossover, which gave a buy signal and the RSI back over 50% level. In addition, the bullish crossover in the ADX chart adds to my conviction. Will watch tomorrow for continuation.
The Next Big Biotech Mover: Ariad Pharma
As you can see, I have a pretty good eye for spotting the big movers in the biotech sector before they take off and explode. The next biotech stock that I believe is setting up for a monster move higher is Ariad Pharmaceuticals (ARIA_), an oncology company focused on the discovery, development and commercialization of medicines for cancer patients.
Ariad Pharmaceuticals ran into some major problems last year when its lead leukemia drug Iclusig was pulled off the market. because it was found to cause severe blood clots and narrowing of blood vessels. The drug has now been returned to the marketplace with a longer warning label that maps out the risks involved with taking the drug. Since the drug has been put back on the market, some rumors have started to make the rounds that Ariad Pharmaceuticals could be a buyout target for Eli Lilly (LLY_) or GlaxoSmithKline (GSK_). Some of those rumors have suggested that ARIA could fetch as much s $20 a share.
Regardless of the rumors, I like to focus on the charts and right now shares of ARIA are starting to show signs technically that large move higher could be in the cards soon.
If you consult the chart for ARIAD Pharmaceuticals, you'll notice that this stock recently formed a double top chart pattern at $9.22 to $9.13 a share. Following that top, shares of ARIA sold off and pulled back and briefly traded below its 50-day moving average. That trip below its 50-day didn't last long and shares of ARIA are now starting to spike higher and begin to move within range of triggering a major breakout trade.
http://www.thestreet.com/story/12535755/1/the-next-big-biotech-mover-ariad-pharma.html
ARIAD to Host Conference Call and Webcast Discussion of Fourth Quarter and Year-End 2013 Financial Results on February 25, 2014
http://www.nasdaq.com/press-release/ariad-to-host-conference-call-and-webcast-discussion-of-fourth-quarter-and-yearend-2013-financial-20140210-00202
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has recently been trading high volume and is about to test resistance at 7.75 which is the previous high. If that break occurs, the stock price should be ripe for a long trade. All technicals are bullish and the short term outlook continues to look bullish.
http://1.bp.blogspot.com/-WIIB_02CTdg/UuGcDcWGcJI/AAAAAAAAZFM/rRODQbjeDvM/s1600/sc.png
the Bulls are able to push through this level
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) The chart is showing a slightly bullish bias. Let’s see whether the stock price can gather enough momentum to break through 6.97. If the Bulls are able to push through this level, there will be another rally towards 7.75.
The stock price looks to be setting up for a move higher here.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) made a nice bounce off its 50-day EMA today and gained more than 4% on solid volume. It is been consolidating gains for nearly 2 weeks. The stock price looks to be setting up for a move higher here. Keep it on watch.
http://3.bp.blogspot.com/-2HjehmRGmhY/Us8Yam_ffqI/AAAAAAAAY5U/P0zUki6bmec/s1600/sc.png
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) continued its bullish bias today. A clear break above 7.75 on heavy volume could trigger further bullish scenario testing 8.95.
http://4.bp.blogspot.com/-I_P0IIYitl8/UsXd8yV_6uI/AAAAAAAAYzM/S09aXInOW_s/s1600/sc.png
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is still holding its breakout point and looking strong. Look at the five big volume sessions. That's serious accumulation. Watch it if the stock breaks yesterday's highs.
http://4.bp.blogspot.com/-wgeaZRdnD1A/UrlJ7WJhClI/AAAAAAAAYsw/OpxeDkd5Mq0/s1600/sc.png
Guten morgen aus Deutschland Frankfurt
3 Stocks Under $10 Moving Higher
http://www.stockpickr.com/3-stocks-under-10-moving-higher.html-10?puc=quo
Dendreon (DNDN) is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. This stock closed up 4.5% to $3.21 in Thursday's trading session.
Thursday's Range: $3.02-$3.23
52-Week Range: $2.23-$7.22
Thursday's Volume: 5.85 million
Three-Month Average Volume: 4.26 million
From a technical perspective, DNDN spiked sharply higher here and broke out above some near-term overhead resistance at $3.15 with strong upside volume. This stock has been uptrending for the last month and change, with shares moving higher from its low of $2.35 to its intraday high of $3.23. During that uptrend, shares of DNDN have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of DNDN within range of triggering another big breakout trade. That trade will hit if DNDN manages to take out Thursday's high of $3.23 and then once it clears more past resistance at $3.41 with high volume.
Traders should now look for long-biased trades in DNDN as long as it's trending above some near-term support levels at $2.88 or at its 50-day of $2.70 and then once it sustains a move or close above those breakout levels with volume that hits near or above 4.26 million shares. If that breakout triggers soon, then DNDN will set up to re-test or possibly take out its next major overhead resistance level at its 200-day of $3.79. Any high-volume move above that level will then give DNDN a chance to re-fill its previous gap down zone from August that started just above $5.
"We are entering an exciting new chapter in the history of medicine, and RBCC is right on the cutting-edge of this new field of regenerative therapy," Palmer said. "I look forward to leading this growing company into a very bright future for our partners and investors."
By acquiring or partnering with up-and-coming regenerative therapy companies, RBCC plans to be well-positioned to capitalize on the big growth in store for the industry. The company invests in technology developed to compete in the biotechnology industry alongside Amgen (NASDAQ:AMGN), Dendreon Corporation (NASDAQ:DNDN), Smith & Nephew (NYSE:SNN) and Pharmaceutical Product Development (NASDAQ:PPDI).
Read more: http://www.nasdaq.com/press-release/rbcc-appoints-new-ceo-to-achieve-regenerative-medicine-goals-20131205-00065#ixzz2mbaQuL5f
The bulls are in full control.
The negative sentiment that led to the last bearish pattern has evaporated. Besides, the signal is suggesting to STAY LONG. It is best to follow the signal and continue to hold this security.
http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=dndn
The Alzheimer's human trial-We could get an interim look any day-it's clearly working with mice
Presentation Detail
Presentation Abstract
Program#/Poster#: 712.11/G35
Presentation Title: Behavioral effects of anatabine in wild-type and transgenic mouse models of Alzheimer’s disease
Location: Halls B-H
Presentation time: Wednesday, Nov 13, 2013, 10:00 AM -11:00 AM
Topic: ++C.03.v. Cognitive function
Authors: *M. VERMA, D. BEAULIEU-ABDELAHAD, F. CRAWFORD, M. MULLAN, D. PARIS;
Roskamp Inst., Sarasota, FL
Abstract: In this study, we have investigated the impact of anatabine, a minor alkaloid present in plant of the Solanacea family on the behavior of a transgenic mouse model of Alzheimer’s disease (AD) and wild-type mice using a battery of behavior tests. In particular, we show that the acute administration of anatabine dose dependently reduces anxiety in wild-type mice. Similarly, a reduction of anxiety was observed following a chronic treatment in wild-type mice. Interestingly, a chronic anatabine treatment initiated in a transgenic mouse model of AD (Tg PS1/APPsw) presenting already pathological Aß deposition and cognitive impairment (active treatment) appears to reduce hyperactivity, disinhibition and to improve social interaction and social memory deficits which affects Tg PS1/APPsw mice. Overall our data show that anatabine improves cognition in Tg PS1/APPsw mice and elicits anxiolytic properties in wild-type mice. Further studies are underway to investigate the impact of anatabine on AD like pathology in Tg PS1/APPsw mice.
Disclosures: M. Verma: None.
Keyword(s): ALZHEIMER'S DISEASE
BEHAVIOR
TRANSGENIC MOUSE
Presentation Abstract
Program#/Poster#: 712.11/G35
Presentation Title: Behavioral effects of anatabine in wild-type and transgenic mouse models of Alzheimer’s disease
Location: Halls B-H
Presentation time: Wednesday, Nov 13, 2013, 10:00 AM -11:00 AM
Topic: ++C.03.v. Cognitive function
Authors: *M. VERMA, D. BEAULIEU-ABDELAHAD, F. CRAWFORD, M. MULLAN, D. PARIS;
Roskamp Inst., Sarasota, FL
Abstract: In this study, we have investigated the impact of anatabine, a minor alkaloid present in plant of the Solanacea family on the behavior of a transgenic mouse model of Alzheimer’s disease (AD) and wild-type mice using a battery of behavior tests. In particular, we show that the acute administration of anatabine dose dependently reduces anxiety in wild-type mice. Similarly, a reduction of anxiety was observed following a chronic treatment in wild-type mice. Interestingly, a chronic anatabine treatment initiated in a transgenic mouse model of AD (Tg PS1/APPsw) presenting already pathological Aß deposition and cognitive impairment (active treatment) appears to reduce hyperactivity, disinhibition and to improve social interaction and social memory deficits which affects Tg PS1/APPsw mice. Overall our data show that anatabine improves cognition in Tg PS1/APPsw mice and elicits anxiolytic properties in wild-type mice. Further studies are underway to investigate the impact of anatabine on AD like pathology in Tg PS1/APPsw mice.
Disclosures: M. Verma: None.
Keyword(s): ALZHEIMER'S DISEASE
BEHAVIOR
TRANSGENIC MOUSE Less
Alzheimers cure, not if its when !!!
look at the letters below his picture.
http://www.michaelmullanroskamp.com/uploads/1/4/1/4/14144382/alzheimers_cure_not_if_its_when_observer.pdf
I think this was the Real reason for the tun to 2,60$ .
Some Insiders like Mullan buy Shares before WE did it .
ASAP trial: Anatabine decreased thyroid autoimmunity
http://www.healio.com/endocrinology/thyroid/news/online/%7B288199cd-9fb4-46e7-8240-9de6a1346786%7D/asap-trial-anatabine-decreased-thyroid-autoimmunity
Let’s jump on our white horse
Market Outlook
Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.
http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=STSI
if stsi went insolvent (i hope not) what would happens with the patents for Anatabine?
Star Scientific Says Shareholder Drug Suit Falls Short
Law360, Los Angeles (October 28, 2013, 9:43 PM ET) -- Nutritional supplements manufacturer Star Scientific Inc. on Friday asked a Virginia federal court to throw out a suit claiming the company misled shareholders about the backgrounds of some of its scientists, saying the consolidated derivative action doesn’t adequately show bad intent.
Shareholders sued Star Scientific in May, claiming the company falsely linked Johns Hopkins University to one of its clinical tests and delayed releasing information about a federal investigation of the company, sending share share prices down 12 and 17 percent, respectively, when those bits of...
http://www.law360.com/articles/483896
Recent Test Makes Star Scientific Even Stronger
n other words, the bears had a chance to torpedo the stock on Monday and Tuesday, and just couldn't get the job done. The fact that the bulls ultimately dismissed the admittedly-reasonable concerns says the psychological undertow for STSI is bullish.
http://www.smallcapnetwork.com/Recent-Test-Makes-Star-Scientific-Even-Stronger-STSI/s/via/1789/article/view/p/mid/3/id/448/
food grade salts of anatabine
United States Patent
Nr. 8,557,999
October 15, 2013
Pharmaceutical, dietary supplement, and food grade salts of anatabine
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=anatabine&OS=anatabine&RS=anatabine
explosive long trade
Signal Update Our system’s recommendation today is to BUY.
The BULLISH STOP LOSS pattern finally received a confirmation because the prices crossed the Stop Loss level which was at 2,0500, and our valid average buying price stands now at 2,2600. The previous SELL recommendation was issued on 09.10.2013, 6 days ago, when the stock price was 1,9200. Since then STSI has risen by +17,71%.
Market Outlook
A rally after a bear setup can occasionally turn into an explosive long trade. We may be on the verge of catching one of them. There is now a strong positive sentiment in the market despite the absence of a bullish pattern. The bullish stop loss is finally confirmed and a BUY signal is generated. Market wants to reward the bulls. It may be now the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd.
http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=STSI
my experience with anatabloc
after another 2 month with anataboc I have ascertained the following:
I have keep my weight.
I am 40 years old and feel like in the end of 20.
I play football with older men (40-50 years), because I could not keep up with our active younger players any more. (20-30 years)
Till this weekend.......
After an soccer match on saturday with older men over 60min and another match on sunday with the younger players over 90min, i feel no muscle pains. The activen players wont let me go any more.
That is a very very good feeling for a 40 years old man.
and for all the shorts here........
We have won the match 3:0
@pipi
have a look at my message (13869) regarding the tea.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91982047
Sometimes, candlestick patterns falter......
The market’s bullish enthusiasm is a fact that unfortunately was not forewarned by a bullish pattern. Our previous SELL signal didn't work out. This happens. Sometimes, candlestick patterns falter. We owe you an apology for that, but this is exactly what we have the stop loss mechanism for. The bullish stop loss of the last bearish pattern is triggered today.
http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=STSI
The sleeping gorilla was woken up.
Quotes from Germany.....
1,741 EUR +20,15% +0,29
1,741 EUR x1,355 (EUR/$) = 2,36 $
still no volume, only 299 shares.
The majority still has no notion.
we have the liftoff !!
Crossing MA50 - MA200
Sep.12 1,90$ - 1,93$ = +0,03
Sep.13 1,91$ - 1,92$ = +0,01
Sep.16 1,92$ - 1,91$ = -0,01
Sep.17 1,93$ - 1,91$ = -0,02
Sep.18 1,93$ - 1,90$ = -0,03
Sep.19 1,94$ - 1,90$ = -0,04
Sep.20 1,95$ - 1,89$ = -0,06
Oct.08 1,96$ - 1,82$ = -0,14
....up up and away !! here is the volume
guys....have you already heard from anatabloc ?
extract from......
Alzheimer's disease is a an irreversible brain disorder with no known cure.
The cause of Alzheimer's disease is not yet known.
http://www.alzheimersreadingroom.com/2010/01/what-is-alzheimers-disease.html
Star at $2,01 after-hours
http://www.nasdaq.com/symbol/stsi/after-hours
Our previous SHORT signal didn't work out
so sorry...shorty !!
It was definitely a day of high anxiety for shorts watching the sudden bullish move.
The bulls now have the upper hand in the market. This bullish enthusiasm caught us off guard without the forewarning of a bullish pattern. Our previous SHORT signal didn't work out. This happens. Sometimes, candlestick patterns falter. We owe you an apology for that, but this is exactly what we have the stop loss mechanism for. The bullish stop loss of the last bearish pattern is triggered today.
http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=STSI
Rheumatology 2.0
look at videos........
http://paper.li/carvicab/1325594128
Who is this Adam ??
https://twitter.com/Roadster1951
Anatabloc works and is very effective
http://baznevis.com/tag/anatabloc/
This would be the best moment to published the study results !!
Crossing MA50 - MA200
Sep.12 1,90$ - 1,93$ = +0,03
Sep.13 1,91$ - 1,92$ = +0,01
Sep.16 1,92$ - 1,91$ = -0,01
Sep.17 1,93$ - 1,91$ = -0,02
Sep.18 1,93$ - 1,90$ = -0,03
Sep.19 1,94$ - 1,90$ = -0,04
Sep.20 1,95$ - 1,89$ = -0,06
Sep.24 1,96$ - 1,88$ = -0,08